Theravectys
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Aug 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
No maintenance fee falls due on this company's record before Nov 21, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,709,799 | Lentiviral gene transfer vectors and their medicinal applications In force · USPTO record | In force | USPTO record | |
| US 8,420,104 | Lentiviral Gene Transfer Vectors and Their Medicinal Applications In force · High confidence | In force | High confidence | |
| US 9,752,160 | Use of Non-Subtype B Gag Proteins for Lentiviral Packaging In force · High confidence | In force | High confidence | |
| US 8,951,535 | Lentiviral vectors containing an MHC class I promoter In force · USPTO record | In force | USPTO record | |
| US 9,657,311 | Lentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence In force · USPTO record | In force | USPTO record | |
| US 9,987,351 | Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1 In force · USPTO record | In force | USPTO record | |
| US 10,864,265 | Lentiviral vectors for expression of hepatitis B virus (HBV) antigens In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 7: 3 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 2 abandoned · 1 no status recorded
Showing 1 to 10 of 10, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/726,286 | Boosting SARS-COV-2 Immunity with a Lentiviral-Based Nasal Vaccine | Jan 17, 2023 | Pending |
| 18/706,610 | Lentiviral Vector for Expression of Human Papillomavirus (HPV) Antigens and Its Implementation in the Treatment of HPV Induced Cancers | Nov 14, 2022 | Pending |
| 18/285,553 | Lentiviral Vector, Lentiviral Particle for Treating Hepatitis B and Its Preparation Method and Application Thereof | Apr 7, 2022 | Pending |
| 18/549,286 | Lentiviral Vectors Targeting Antigens to Mhc-Ii Pathway and Inducing Protective CD8+ and CD4+ T-Cell Immunity in a Host | Mar 11, 2022 | Pending |
| 18/030,102 | Lentiviral Vectors Enabling Routing Antigens to Mhc-Ii Pathway and Inducing CD4+ and CD8+ T-Cell Responses in a Host | Oct 15, 2021 | Pending |
| 18/245,987 | High Throughput Methods and Products for SARS-COV-2 Sero-Neutralization Assay | Sep 21, 2021 | Pending |
| 18/005,146 | SARS-COV-2 Immunogenic Compositions, Vaccines, and Methods | Jul 15, 2021 | Pending |
| 16/931,986 | Lentiviral Vectors for Regulated Expression of a Chimeric Antigen Receptor Molecule | Jul 17, 2020 | Abandoned |
| 15/673,454 | Use of Non-Subtype B Gag Proteins for Lentiviral Packaging | Aug 10, 2017 | Abandoned |
| 14/416,617 | Jul 25, 2013 | No status recorded |